Amplia Therapeutics (ASX:ATX) Total Receivables: A$4.78 Mil (As of Mar. 2026)


ASX:ATX Amplia Therapeutics Ltd ASX:ATX
36 GF Score
Price A$0.15
! 2 Warning Signs
View Full Analysis

What is Amplia Therapeutics Total Receivables?

Amplia Therapeutics ASX:ATX +3.45% 36 Total Receivables is A$4.78 Mil as of Mar. 2026. GuruFocus rates ASX:ATX with a GF Score™ of 36/100. The stock has 2 warning signs investors should review.

Amplia Therapeutics's Total Receivables for the quarter that ended in Mar. 2026 was A$4.78 Mil.

Amplia Therapeutics Total Receivables Related Terms

Amplia Therapeutics Total Receivables Historical Data

* Premium members only.

The historical data trend for Amplia Therapeutics's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amplia Therapeutics Total Receivables Chart

Amplia Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.84 1.15 3.18 3.77 4.78

Amplia Therapeutics Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.18 0.00 3.77 0.00 4.78
ASX:ATX
36GF Score
Amplia Therapeutics Ltd ASX:ATX
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amplia Therapeutics Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of A$4.78 Mil mean?
Amplia Therapeutics (ASX:ATX) has a Total Receivables of A$4.78 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Amplia Therapeutics and its competitors.
Is Amplia Therapeutics' Total Receivables too high?
Amplia Therapeutics' current Total Receivables is A$4.78 Mil. Overall, Amplia Therapeutics has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Amplia Therapeutics' Total Receivables compare to VRTX and REGN?
Amplia Therapeutics' Total Receivables of A$4.78 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Amplia Therapeutics and its competitors. Amplia Therapeutics's current Total Receivables is A$4.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amplia Therapeutics stock overvalued right now?
Amplia Therapeutics (ASX:ATX) has a current Total Receivables of A$4.78 Mil. The current Total Receivables is A$4.78 Mil. Amplia Therapeutics' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Amplia Therapeutics (ASX:ATX), the current Total Receivables is A$4.78 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Amplia Therapeutics Business Description

Other Exchanges INNMF:USA
Address 90 William Street, Level 5, Melbourne, VIC, AUS, 3000
Amplia Therapeutics Ltd is an Australian, clinical-stage, drug development company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is focused on the development of these drug candidates for potential use in multiple indications in oncology (e.g. pancreatic cancer) and chronic fibrotic diseases. Its molecule, AMP945 is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and preclinical development for idiopathic pulmonary fibrosis (IPF).
36GF Score

Get the complete analysis for ASX:ATX

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.15
Price